CF Collaboration Momentum ReCode has received funding support from the CF Foundation and is collaborating with New York Medical College on an inhaled mRNA therapy for cystic fibrosis, signaling strong opportunities for CF-focused partnerships, sponsored trials, and co-development around inhaled delivery platforms.

Lung Delivery Focus ReCode's SORT LNP platform enables precise delivery beyond the liver, with inhaled mRNA data presented at the ATS conference and a CF inhaled program in collaboration with NYMC, creating opportunities to partner with pulmonary drug developers, inhaled-delivery device makers, and related CROs to scale non-hepatic delivery programs.

Clinical Partnership Potential With a clinical-stage profile and ongoing inhaled programs for cystic fibrosis, ReCode offers potential for licensing, co-development, or strategic partnerships with larger biopharma seeking to expand gene therapies and advanced mRNA delivery capabilities.

Funding Signals Funding activity and ongoing investor interest signal opportunities to engage growth-focused investors and strategic funders for sponsored trials, platform expansion, or milestone-based collaborations with ReCode.

Platform Advantage Platform superiority for non-hepatic delivery positions ReCode as a potential partner for other gene therapy developers needing non-liver targeting; explore licensing, sponsored research, or joint development agreements to monetize the SORT LNP technology.